<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01664975</url>
  </required_header>
  <id_info>
    <org_study_id>hnslblzlzx2011-3</org_study_id>
    <nct_id>NCT01664975</nct_id>
  </id_info>
  <brief_title>Treatment of Peripheral T-cell Lymphoma</brief_title>
  <official_title>A Randomized Controlled Multi-center Clinical Trial on Treatment of Peripheral T-cell Lymphoma With DGPT Regiment (Gemcitabine,Cisplatin,Prednisone ,Thalidomide )</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mingzhi Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhengzhou University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of GDPT regiment&#xD;
      (gemcitabine，cisplatin,Prednisone ,Thalidomide&#xD;
&#xD;
      ) for patients with Peripheral T-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Peripheral T-cell lymphoma usually have a bad prognosis. These patients cannot&#xD;
      be treated successfully with the conventional chemotherapy of CHOP. The investigators have&#xD;
      been proceeding this trial to evaluate the efficacy and safety of the combination&#xD;
      chemotherapy regiment GDPT regiment (gemcitabine，cisplatin,Prednisone ,Thalidomide&#xD;
&#xD;
      ) in the patients with Peripheral T-cell lymphoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>up to end of follow-up-phase (approximately 24 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>every 6 weeks,up to completion of treatment(approximately 18 weeks )</time_frame>
    <description>21 days(3 weeks) for one cycle,Efficacy was evaluated every two cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to the date of death (approximately 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Survival Time</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Peripheral T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>GDPT regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GDPT(gemcitabine,cisplatin,Prednisone,Thalidomide) regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHOP regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDPT regimen</intervention_name>
    <description>GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.</description>
    <arm_group_label>GDPT regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOP regimen</intervention_name>
    <description>CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.</description>
    <arm_group_label>CHOP regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age range 14-70 years old; ECOG performance status 0-2; Estimated survival time &gt; 3 months&#xD;
        Histological confirmed Peripheral T cell lymphoma None of chemotherapy or radiotherapy has&#xD;
        been previously used None of chemotherapy contraindication: hemoglobin ≥ 90 g/dl,&#xD;
        neutrophil ≥ 1.5×109/L, platelet ≥ 100×109/L, ALT and AST ≤ 2×ULN, serum bilirubin ≤&#xD;
        1.5×ULN, serum creatine ≤ 1.5×upper limitation of normal (ULN), Serum Albumin ≥ 30g/L,&#xD;
        serum plasminogen is normal (Inclusion Criteria of 1,3,6 groups ) At least one measurable&#xD;
        lesion None of other serious diseases, cardiopulmonary function is normal Pregnancy test of&#xD;
        women at reproductive age must be negative Patients could be followed up None of other&#xD;
        relative treatments including the traditional Chinese medicine, immunotherapy,biotherapy&#xD;
        except anti-bone metastasis therapy and other symptomatic treatments.&#xD;
&#xD;
        volunteers who signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Disagreement on blood sample collection Patients allergic of any of drug in this regimen or&#xD;
        with metabolic disorder Pregnant or lactating women Serious medical illness likely to&#xD;
        interfere with participation Serious infection Primitive or secondary tumors of central&#xD;
        nervous system Chemotherapy or radiotherapy contraindication The evidence of CNS metastasis&#xD;
        History of peripheral nervous disorder or dysphrenia patients participating in other&#xD;
        clinical trials patients taking other antitumor drugs patients estimated to be unsuitable&#xD;
        by investigato&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingzhi Zhang, Pro,Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oncology Department of The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 10, 2012</study_first_submitted>
  <study_first_submitted_qc>August 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2012</study_first_posted>
  <results_first_submitted>August 10, 2016</results_first_submitted>
  <results_first_submitted_qc>August 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 5, 2016</results_first_posted>
  <last_update_submitted>August 10, 2016</last_update_submitted>
  <last_update_submitted_qc>August 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhengzhou University</investigator_affiliation>
    <investigator_full_name>Mingzhi Zhang</investigator_full_name>
    <investigator_title>the director of oncology department of the first affiliated hospital</investigator_title>
  </responsible_party>
  <keyword>Peripheral T-cell lymphoma;chemotherapy;</keyword>
  <keyword>RR;PFS;OS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GDPT Regimen</title>
          <description>GDPT(gemcitabine,cisplatin,Prednisone,Thalidomide) regimen&#xD;
GDPT regimen: GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.</description>
        </group>
        <group group_id="P2">
          <title>CHOP Regimen</title>
          <description>CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen&#xD;
CHOP regimen: CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GDPT Regimen</title>
          <description>GDPT(gemcitabine,cisplatin,Prednisone,Thalidomide) regimen&#xD;
GDPT regimen: GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.</description>
        </group>
        <group group_id="B2">
          <title>CHOP Regimen</title>
          <description>CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen&#xD;
CHOP regimen: CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="103"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="16" upper_limit="69"/>
                    <measurement group_id="B2" value="51" lower_limit="15" upper_limit="70"/>
                    <measurement group_id="B3" value="55" lower_limit="15" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival</title>
        <time_frame>up to end of follow-up-phase (approximately 24 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GDPT Regimen</title>
            <description>GDPT(gemcitabine,cisplatin,Prednisone,Thalidomide) regimen&#xD;
GDPT regimen: GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.</description>
          </group>
          <group group_id="O2">
            <title>CHOP Regimen</title>
            <description>CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen&#xD;
CHOP regimen: CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate</title>
        <description>21 days(3 weeks) for one cycle,Efficacy was evaluated every two cycles</description>
        <time_frame>every 6 weeks,up to completion of treatment(approximately 18 weeks )</time_frame>
        <posting_date>09/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>up to the date of death (approximately 5 years)</time_frame>
        <posting_date>09/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Survival Time</title>
        <time_frame>24 months</time_frame>
        <posting_date>12/2016</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>GDPT Regimen</title>
          <description>GDPT(gemcitabine,cisplatin,Prednisone,Thalidomide) regimen&#xD;
GDPT regimen: GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.</description>
        </group>
        <group group_id="E2">
          <title>CHOP Regimen</title>
          <description>CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen&#xD;
CHOP regimen: CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade3/4 myelosuppression</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>digestive tract toxicity</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mingzhi Zhang</name_or_title>
      <organization>Zhengzhou University</organization>
      <phone>0371-66295564</phone>
      <email>mingzhi_zhang@126.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01664975
org study id: hnslblzlzx2011-3
nct id: NCT01664975
lead sponsor: 
collaborator: 
has dmc: No
The purpose of this study is to evaluate the efficacy and safety of GDPT regiment
      (gemcitabine，cisplatin,Prednisone ,Thalidomide

      ) for patients with Peripheral T-cell lymphoma.
Patients with Peripheral T-cell lymphoma usually have a bad prognosis. These patients cannot
      be treated successfully with the conventional chemotherapy of CHOP. The investigators have
      been proceeding this trial to evaluate the efficacy and safety of the combination
      chemotherapy regiment GDPT regiment (gemcitabine，cisplatin,Prednisone ,Thalidomide

      ) in the patients with Peripheral T-cell lymphoma.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Progression-free Survival
time frame: up to end of follow-up-phase (approximately 24 months)
measure: Response Rate
time frame: every 6 weeks,up to completion of treatment(approximately 18 weeks )
description: 21 days(3 weeks) for one cycle,Efficacy was evaluated every two cycles
measure: Overall Survival
time frame: up to the date of death (approximately 5 years)
measure: Median Survival Time
time frame: 24 months
arm group label: GDPT regimen
arm group type: Experimental
description: GDPT(gemcitabine,cisplatin,Prednisone,Thalidomide) regimen
arm group label: CHOP regimen
arm group type: Experimental
description: CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
intervention type: Drug
intervention name: GDPT regimen
description: GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
arm group label: GDPT regimen
intervention type: Drug
intervention name: CHOP regimen
description: CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
arm group label: CHOP regimen
criteria: 
gender: All
minimum age: 14 Years
maximum age: 70 Years
healthy volunteers: No
last name: Mingzhi Zhang, Pro,Dr
role: Principal Investigator
affiliation: The First Affiliated Hospital of Zhengzhou University
facility: 
country: China
responsible party type: Sponsor-Investigator
investigator affiliation: Zhengzhou University
investigator full name: Mingzhi Zhang
investigator title: the director of oncology department of the first affiliated hospital
mesh term: Lymphoma
mesh term: Lymphoma, T-Cell
mesh term: Lymphoma, T-Cell, Peripheral
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 